Rahul Singhvi, Resilience CEO

Re­silience part­ners with the Cal­i­for­nia In­sti­tute for Re­gen­er­a­tive Med­i­cine to help cell ther­a­py star­tups

As Re­silience keeps up the mo­men­tum post-Se­ries D, the bio­man­u­fac­tur­er has reeled in an­oth­er part­ner­ship, this time in the Gold­en State.

The com­pa­ny an­nounced that it has been named by the Cal­i­for­nia In­sti­tute for Re­gen­er­a­tive Med­i­cine (CIRM) as one of its ini­tial in­dus­try re­source part­ners with­in its in­dus­try al­liance pro­gram (IAP).

The deal will have Re­silience sup­port trans­la­tion­al and clin­i­cal phase grant ap­pli­ca­tions, in­clud­ing TRAN, CLIN1 and CLIN2 grants, for cell ther­a­py pro­grams. The deal al­so has the po­ten­tial to ex­pand to oth­er modal­i­ties such as gene ther­a­pies and bi­o­log­ics in the fu­ture. Re­silience will pro­vide project con­sul­ta­tion that could aid CIRM ap­pli­cants in draft­ing man­u­fac­tur­ing plans and bud­gets for their ap­pli­ca­tions to the pro­gram.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.